Eli Lilly is Seizing the Future of Pain Medicine! SiteOne Therapeutics Deal Aims to Advance Opioid Alternatives!
Reading Time: 3 minutes
The pharmaceutical giant Eli Lilly (LLY) is acquiring the private company SiteOne Therapeutics and its product line of small-molecule painkillers as part of a deal worth up to $1 billion, according to a press release issued on Tuesday, May 27, 2025. Eli Lilly's shares rose by nearly 2% during the trading day to $725.22. SiteOne Therapeutics - a pioneer in non-opioid pain therapy SiteOne Therapeutics is an emerging, clinically active biotechnology company specializing in the development of highly selective, non-opioid painkillers. The focus...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
